You are viewing: Spain Compounding Pharmacy Market analysis
Part of: Compounding Pharmacy Market (Global)

The Spain Compounding Pharmacy Market was valued at $129.3 Million in 2025 and projected to reach to $180.1 Million by 2030, representing a compound annual growth rate of CAGR 6.9%. Spain's compounding pharmacy market is positioned for sustained growth driven by increasing healthcare personalization and regulatory support.

Spain Compounding Pharmacy Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Spain Compounding Pharmacy Market Trends and Insights

  • This expansion reflects Spain's increasing demand for personalized pharmaceutical solutions and tailored medication formulations that address patient-specific needs.
  • The Spanish healthcare system's growing recognition of compounding pharmacies as essential providers of customized treatments is driving market penetration across both urban and regional healthcare networks. The 6.9% compound annual growth rate in Spain significantly outpaces the global average of 5.7%, indicating strong regional momentum.
  • Spain's aging population, coupled with rising prevalence of chronic diseases and heightened patient preference for individualized therapies, creates favorable conditions for compounding pharmacy services.
  • Between 2025 and 2030, Spain is positioned to capture increasing market share within Europe's broader compounding pharmacy sector, supported by regulatory frameworks that facilitate specialized pharmaceutical preparation and distribution..

Key Market Statistics

  • CAGR (2025-2030) CAGR 6.9%
  • Market Size, 2025 ~USD 129.3 Million
  • Forecast, 2030 ~USD 180.1 Million
  • Country Spain

Spain Compounding Pharmacy Market Overview

Market Valuation Growth :

Spain's compounding pharmacy market is valued at $129.3 million in 2025, with a projected CAGR of 6.9% through 2030, reaching $180.1 million. This growth rate outpaces the global average of 5.7%, indicating Spain's accelerating adoption of personalized pharmaceutical solutions.

Healthcare System Integration :

The Spanish healthcare system is increasingly recognizing compounding pharmacies as essential providers of tailored medication formulations. This institutional support drives market expansion and legitimizes compounding services within Spain's regulated pharmaceutical landscape.

Personalized Medicine Demand :

Spanish patients and healthcare providers are demonstrating growing demand for patient-specific pharmaceutical solutions. This shift toward personalized medicine reflects evolving treatment paradigms and the need for customized dosages and formulations unavailable in commercial markets.

Regional Market Opportunity :

With a $50.8 million growth opportunity between 2025 and 2030, Spain represents a significant expansion market within Europe. The country's aging population and chronic disease prevalence create sustained demand for specialized compounding services.

Spain Compounding Pharmacy Market Dynamics

  • The Spanish healthcare system's recognition of compounding pharmacies as critical service providers will continue to expand market accessibility and patient adoption rates.
  • Healthcare professionals are increasingly prescribing customized formulations for complex conditions, pediatric patients, and individuals with medication allergies or sensitivities. Looking ahead to 2030, Spain's market will benefit from technological advancements in compounding practices, enhanced regulatory frameworks, and growing integration with hospital and clinical pharmacy networks.
  • The aging Spanish population and rising prevalence of chronic diseases will sustain demand for tailored pharmaceutical solutions, while increased awareness among patients and healthcare providers will drive market penetration across urban and regional healthcare facilities..

Market Ecosystem

logo-mobile

COMPOUNDING PHARMACY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Provides sterile and non-sterile compounding services, including ready-to-dispense and ready-to-administer personalized medicines for pharmacies, hospitals, and clinics | Its compounding operations support customized strengths, dosage forms, ingredient requirements, and therapies where commercially available medicines may be unsuitable or unavailable. Enables healthcare providers to address patient-specific medication requirements, drug shortages, discontinued products, allergies, and dosage-form limitations while outsourcing complex sterile and non-sterile compounding activities.
company logo
Operates both a 503A compounding pharmacy for patient-specific prescriptions and an FDA-registered 503B outsourcing facility for office-use medications | Its portfolio includes compounded preparations across multiple therapeutic areas and dosage forms, supported by sterile batch testing and cGMP processes at the 503B facility. Expands access to individualized medicines and multiple strengths and dosage forms while enabling healthcare providers to procure larger-scale compounded products from a regulated outsourcing facility.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Spain's compounding pharmacy market will grow from $129.3M (2025) to $180.1M (2030) at a 6.9% CAGR, outpacing global growth.
    • Spain's aging demographic and chronic disease prevalence are primary drivers of demand for personalized compounding pharmacy solutions.
    • Spain's regulatory environment supports specialized pharmaceutical preparation, enabling market expansion and service diversification.
    • Spain is positioned as a high-growth European market, with compounding pharmacies increasingly integrated into mainstream healthcare delivery.

    Compounding Pharmacy Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment HORMONE REPLACEMENT THERAPIES (Therapeutic Application)
    Forecast Period 2025–2030
    Growth Rate CAGR of 5.7% from 2025 to 2030
    Largest Segment PHARMACEUTICAL DOSAGE ALTERATION (Compounding Type)
    Market Size Base Year (Billions) ~USD 14.71 (2025)
    Revenue Forecast (Billions) ~USD 19.41 (2030)
    Segments Covered Product, Compounding Type, Therapeutic Application

    Spain Compounding Pharmacy Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Product

    • Nasal Drugs
    • Ophthalmic Drugs
    • Oral Drugs
    • Other Products
    • Parenteral Drugs
    • Rectal Drugs
    • Topical Drugs

    By Compounding Type

    • Currently Unavailable Pharmaceutical Manufacturing
    • Pharmaceutical Dosage Alteration
    • Pharmaceutical Ingredient Alteration

    By Therapeutic Application

    • Dermal Disorders
    • Hormone Replacement Therapies
    • Nutritional Supplements
    • Other Therapeutic Applications
    • Pain Management

    SPAIN: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ADULTS176.8199.3219.9238.6255.3270.5286.7304.96.8
    GERIATRIC PATIENTS79.288.797.1104.6111.1116.8122.9129.75.9
    PEDIATRIC PATIENTS50.557.764.671.17782.788.995.78.2
    TOTAL306.5345.6381.6414.3443.4470498.5530.36.8

    Target Audience

    • Pharmaceutical Manufacturers : Spanish and international pharmaceutical companies need market intelligence to identify partnership opportunities with compounding pharmacies, develop customizable formulations, and expand distribution networks within Spain's growing personalized medicine segment.
    • Healthcare Investors : Private equity firms, venture capital investors, and healthcare funds require Spain-specific market data to evaluate investment opportunities in compounding pharmacy chains, assess growth potential, and make informed capital allocation decisions.
    • Pharmacy Operators : Independent and chain pharmacy owners in Spain need market insights to understand growth opportunities, competitive positioning, and demand drivers for compounding services to optimize service offerings and revenue streams.
    • Healthcare Consultants : Management consulting firms and healthcare advisors require detailed Spain market analysis to support client strategy development, market entry planning, and operational optimization for pharmaceutical and healthcare organizations.
    • Regulatory and Policy Bodies : Spanish healthcare authorities, pharmaceutical regulatory agencies, and policy makers need market data to inform healthcare policy decisions, regulatory frameworks, and resource allocation for compounding pharmacy oversight and integration.

    Key Companies in the Spain Compounding Pharmacy Market

    CompanyHQOwnershipStrongest segments
    BAXTERUnited StatesPublic CompanyMedical Products & Therapies (IV, infusion, parenteral nutrition, renal-related therapies),Healthcare Systems & Technologies (smart beds, monitoring, OR integration, surgical equipment),Pharmaceuticals (generic and specialty injectables, inhaled anesthetics, compounding services),
    FAGRONBelgiumPublic CompanyEssentials (APIs, excipients, bases),Brands (derma, immunology, hair, scar care),Compounding Services,

    BAXTER

    Baxter is a publicly traded American healthcare company founded in 1931 that employs 37,500 people. The company operates as a major medical device and pharmaceutical manufacturer serving global markets.

    FAGRON

    Fagron is a publicly traded Belgian pharmaceutical company founded in 1990 with 4,880 employees. The company focuses on pharmaceutical compounding and specialty pharmacy solutions.

    Reasons to Buy this Report

    • Spain-Specific Market Sizing : Obtain precise valuation data for Spain's compounding pharmacy market with verified figures for 2025 ($129.3M) and 2030 forecasts ($180.1M), enabling accurate business planning and investment decisions specific to the Spanish market.
    • Competitive Positioning Intelligence : Understand Spain's unique market dynamics, healthcare system integration, and regulatory environment to identify competitive advantages and market entry strategies tailored to Spanish pharmaceutical and healthcare sectors.
    • Growth Trajectory Analysis : Leverage Spain's 6.9% CAGR data to benchmark performance against global trends (5.7%) and identify why Spain outperforms regional averages, informing expansion strategies and resource allocation decisions.
    • Stakeholder Engagement Strategy : Access insights into Spanish healthcare provider adoption, patient demand patterns, and institutional support for compounding services to develop targeted engagement strategies for hospitals, pharmacies, and healthcare networks.
    • Investment and Expansion Planning : Utilize comprehensive Spain market data to evaluate investment opportunities, forecast revenue potential, and develop business cases for establishing or expanding compounding pharmacy operations within the Spanish healthcare ecosystem.

    Frequently asked questions

    What is the current size of Spain's compounding pharmacy market?

    Spain's compounding pharmacy market was valued at $129.3 million in 2025 and is expected to reach $180.1 million by 2030.

    What is the growth rate for Spain's compounding pharmacy market?

    Spain's compounding pharmacy market is growing at a compound annual growth rate (CAGR) of 6.9% from 2025 to 2030.

    Why is Spain's compounding pharmacy market growing faster than the global average?

    Spain's 6.9% CAGR exceeds the global 5.7% average due to an aging population, rising chronic disease prevalence, and strong patient demand for personalized medication solutions.

    What factors are driving growth in Spain's compounding pharmacy sector?

    Key drivers include Spain's demographic shifts toward an older population, increased prevalence of chronic conditions, patient preference for individualized therapies, and supportive regulatory frameworks.

    How does Spain's compounding pharmacy market compare to other European markets?

    Spain's 6.9% CAGR positions it as a high-growth European market, with compounding pharmacies increasingly recognized as essential providers within Spain's healthcare system.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the compounding pharmacy market. We conducted exhaustive secondary research to gather information on the market, its peer markets, and its parent market. The team then validated these findings, assumptions, and sizing with industry experts across the value chain through primary research. We used both top-down and bottom-up approaches to estimate total market size. We then used data triangulation to estimate market size by segment and subsegment.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the compounding pharmacy market. The secondary sources used for this study include US Food and Drug Administration (FDA), American Pharmacists Association (APhA), International Academy of Compounding Pharmacists (IACP), National Community Pharmacists Association (NCPA), Parenteral Drug Association (PDA), American Society of Health-System Pharmacists (ASHP), Pharmacy Compounding Accreditation Board (PCAB), European Directorate for the Quality of Medicines & HealthCare (EDQM), European Medicines Agency (EMA), International Pharmaceutical Federation (FIP), Journal of Compounding & Specialty Pharmacy (JCSP), National Center for Biotechnology Information (NCBI), Pharmaceutical Research and Manufacturers of America (PhRMA), Pharma & Biopharma Outsourcing Association (PBOA), and World Journal of Pharmaceutical Research (WJPR). Secondary sources also include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis. These sources were also used to obtain key information on major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    We conducted in-depth interviews with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. We interviewed primary sources from both the supply and demand sides of the market to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Compounding Pharmacy Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    We estimated the global size of the compounding pharmacy market using multiple approaches. We used a detailed market estimation approach to estimate and validate the market value and other dependent submarkets. We also used these methods extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following.

    Compounding Pharmacy Market: Top-Down and Bottom-Up Approach

    Compounding Pharmacy Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the market size using the process described above, we divided the total market into several segments and subsegments. To complete the overall market analysis and obtain precise statistics for all segments and subsegments, we used data triangulation and market breakdown methods where applicable. We triangulated the data by examining factors and trends from both the demand and supply sides.

    Market Definition

    A compounding pharmacy is a specialized practice in which a licensed pharmacist combines, mixes, or alters raw drug ingredients to formulate customized medications tailored to individual patients' unique health needs. This process allows pharmacists to create pharmaceutical products in various forms, such as liquids, creams, gels, or capsules, and can be vital for patients with specific allergies, intolerances, or those needing dosages not commercially available. Compounding pharmacists often work closely with healthcare providers to develop formulas that address particular medical conditions, ensuring that each preparation is safe, effective, and personalized to optimize patient care. Additionally, compounding pharmacies adhere to stringent regulatory standards to maintain the integrity and quality of the medications they produce.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Compounding Pharmacies
    • Research & Consulting Firms
    • Academic Medical Centers
    • Government Regulatory & Research Organizations
    • Quality Assurance & Accreditation Bodies
    • Clinical Research Institutes

    Report Objectives

    • To define, describe, and forecast the compounding pharmacy market based on product, compounding type, therapeutic application, sterility, end user, and region
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall compounding pharmacy market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to five regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), and the Middle East & Africa (GCC Countries and the Rest of Middle East & Africa)
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • A further breakdown of the Rest of Asia Pacific compounding pharmacy market into countries
    • A further breakdown of the Rest of Europe compounding pharmacy market into countries
    • A further breakdown of the Rest of Latin America compounding pharmacy market into countries

    Company Information

    • Detailed analysis and profiling of additional market players (up to five).
     

     

    Get the Full Compounding Pharmacy Market Report

    Full forecast, segment splits, and company analysis for all Compounding Pharmacy Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status